GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cancer Genetics Inc (NAS:CGIX) » Definitions » Repurchase of Stock

Cancer Genetics (Cancer Genetics) Repurchase of Stock : $0.00 Mil (TTM As of Dec. 2020)


View and export this data going back to 2013. Start your Free Trial

What is Cancer Genetics Repurchase of Stock?

Cancer Genetics's Repurchase of Stock for the three months ended in Dec. 2020 was $0.00 Mil.

Cancer Genetics's Repurchase of Stock for the trailing twelve months (TTM) ended in Dec. 2020 was $0.00 Mil.


Cancer Genetics Repurchase of Stock Historical Data

The historical data trend for Cancer Genetics's Repurchase of Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cancer Genetics Repurchase of Stock Chart

Cancer Genetics Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Repurchase of Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cancer Genetics Quarterly Data
Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
Repurchase of Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Cancer Genetics Repurchase of Stock Calculation

A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of Stock represents the cash outflow to reacquire common stock during the period.

Repurchase of Stock for the trailing twelve months (TTM) ended in Dec. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cancer Genetics Repurchase of Stock Related Terms

Thank you for viewing the detailed overview of Cancer Genetics's Repurchase of Stock provided by GuruFocus.com. Please click on the following links to see related term pages.


Cancer Genetics (Cancer Genetics) Business Description

Traded in Other Exchanges
N/A
Address
201 Route 17 North, 2nd Floor, Meadows Office Complex, Rutherford, NJ, USA, 07070
Cancer Genetics Inc through its vivoPharm subsidiary offers proprietary preclinical test systems supporting clinical diagnostic offerings at early stages, valued by the pharmaceutical industry, biotechnology companies, and academic research centers. The company is focused on precision and translational medicine to drive drug discovery and novel therapies. Its subsidiary, vivoPharm specializes in conducting studies tailored to guide drug development, starting from compound libraries and ending with a comprehensive set of in vitro and in vivo data and reports, as needed for Investigational New Drug filings. VivoPharm operates in The Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC) accredited and GLP compliant audited facilities.
Executives
Ralf Brandt officer: President, Discovery Services 201 ROUTE 17 N., 2ND FLOOR, RUTHERFORD NJ 07070
Michael Glenn Miles officer: Chief Financial Officer C/O CANCER GENETICS INC., 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070
Franklyn G Prendergast director
Chaganti Raju S.k. director 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070
Edmund Cannon director 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070
Geoffrey E. Harris director 8 HARTLEY FARMS ROAD, MORRISTOWN NJ 07960
Howard Mcleod director 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070
John Pappajohn director 1660 WALT WHITMAN ROAD, SUITE 105, MELVILLE NY 11747
John A Roberts officer: Chief Executive Officer C/O CANCER GENETICS, INC., 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070
William Lansing Finger officer: EVP Precision Medicine 201 ROUTE 17N., 2ND FLOOR, RUTHERFORD NJ 07070
Michael Brian Mccartney officer: Chief Commercial Officer C/O CANCER GENETICS, INC., 201 ROUTE 17 N, 2ND FLOOR, RUTHERFORD NJ 07070
Rita Shaknovich officer: Chief Medical Officer C/O CANCER GENETICS, INC. 201 ROUTE 17N, 2ND FLOOR, RUTHERFORD NJ 07070
Thomas F Widmann director 201 ROUTE 17 N., 2ND FLOOR, RUTHERFORD NJ 07070
Michael J. Welsh director UNIV. OF IOWA CARVER COLLEGE OF MEDICINE, DEPT. OF INTERNAL MEDICINE, 500 EMRB, IOWA CITY IA 52242
Igor Gitelman officer: Chief Accounting Officer 201 ROUTE 17 N., 2ND FLOOR, RUTHERFORD NJ 07070

Cancer Genetics (Cancer Genetics) Headlines

From GuruFocus

Cancer Genetics and StemoniX Sign Definitive Agreement to Merge

By Marketwired Marketwired 08-24-2020

Cancer Genetics, Inc. Announces Strategic Transactions

By Marketwired Marketwired 07-16-2019